Antileishmanial activity of antimonials entrapped in liposomes

New, R. R. C.; Chance, Michaël La; Thomas, Stephen C.; Peters, W.

doi:10.1038/272055a0

Cited by 180 publications

(49 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,10 Over the past decades, liposomes have demonstrated an increase in the therapeutic efficacy of several drugs. [11][12][13][14][15][16][17][18] Depending upon their physical properties, liposomes are recognized as foreign particles after in vivo administration and are easily cleared by the reticuloendothelial system that harbors Leishmania parasites. [19][20][21] Thus, the association or incorporation of chemotherapeutic agents in liposomes has immense therapeutic benefits against the intracellular infection of Leishmania.…”

Section: Introductionmentioning

confidence: 99%

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis

Want

Islammudin

Chouhan

et al. 2017

IJN

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis

Want

Islammudin

Chouhan

et al. 2017

IJN

View full text Add to dashboard Cite

“…Although powerful antileishmanial agents, these drugs remain a second line of defense because of their severe toxicities (3). However, the antimonial agents, pentamidine, and amphotericin B, when encapsulated in liposomes, are more effective for the treatment of leishmaniasis and are less toxic than the free drugs (4,6,15). Reduced toxicity and an improved therapeutic index with liposomal formulations, especially of amphotericin B, represent an alternative for the treatment of human visceral leishmaniasis (6,20).…”

mentioning

confidence: 99%

Antileishmanial Activities of Stearylamine-Bearing Liposomes

Dey

Anam

Afrin

et al. 2000

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Here we report the activity of liposomes comprising egg phosphatidylcholine (PC) and stearylamine (SA) against Leishmania donovani parasites. Both promastigotes and intracellular amastigotes in vitro and in vivo were susceptible to SA-PC liposomes. A single dose of 55 mg of SA-PC liposomes/animal could significantly reduce the hepatic parasite burden by 85 and 68% against recent and established experimental visceral leishmaniasis, respectively, suggesting their strong therapeutic potential.

show abstract

“…61 Liposomes with different surface charge (anionic and neutral) were subsequently tested, 62 but only recently, a robust effective treatment against infection with SSG-resistant Leishmania parasites in mice has been demonstrated, using cationic PC-stearylamine liposomes. When the charged …”

Section: Liposomesmentioning

confidence: 99%

Nanostructured delivery systems with improved leishmanicidal activity: a critical review

Bruni¹,

Stella²,

Giraudo³

et al. 2017

IJN

View full text Add to dashboard Cite

Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites of the genus Leishmania , which are responsible for numerous clinical manifestations, such as cutaneous, visceral, and mucocutaneous leishmaniasis, depending on the site of infection for particular species. These complexities threaten 350 million people in 98 countries worldwide. Amastigotes living within macrophage phagolysosomes are the principal target of antileishmanial treatment, but these are not an easy target as drugs must overcome major structural barriers. Furthermore, limitations on current therapy are related to efficacy, toxicity, and cost, as well as the length of treatment, which can increase parasitic resistance. Nanotechnology has emerged as an attractive alternative as conventional drugs delivered by nanosized carriers have improved bioavailability and reduced toxicity, together with other characteristics that help to relieve the burden of this disease. The significance of using colloidal carriers loaded with active agents derives from the physiological uptake route of intravenous administered nanosystems (the phagocyte system). Nanosystems are thus able to promote a high drug concentration in intracellular mononuclear phagocyte system (MPS)-infected cells. Moreover, the versatility of nanometric drug delivery systems for the deliberate transport of a range of molecules plays a pivotal role in the design of therapeutic strategies against leishmaniasis. This review discusses studies on nanocarriers that have greatly contributed to improving the efficacy of antileishmaniasis drugs, presenting a critical review and some suggestions for improving drug delivery.

show abstract

Antileishmanial activity of antimonials entrapped in liposomes

Cited by 180 publications

References 8 publications

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis

Antileishmanial Activities of Stearylamine-Bearing Liposomes

Nanostructured delivery systems with improved leishmanicidal activity: a critical review

Contact Info

Product

Resources

About